Combination of non-selective HDACi with immune-activating antibodies such as anti-CD40, anti-CD137, or with immune checkpoint blockers allowed researchers to obtain tumor eradication through similar biological mechanisms such as exacerbated phagocytosis of dead tumor cells, the optimization of antigen presentation by APC, an increase in T cells and a decrease of Tregs in the tumor microenvironment [24,60,81] (Table 6). The gene discussed is CD40; the disease is neoplasm.